In the United States alone, cancer is responsible for more than half a million deaths and $100 billion of care expenditure annually?

One major hurdle to finding effective medicines for cancer is the underlying heterogeneity of the disease. These differences result in expensive clinical trial failures during the development phase, and ineffective treatments for large proportions of patients once a drug is on the market.

Clinical development faces the same hurdles. The failure rate of drugs in Phase 2 or Phase 3 efficacy trials is high, largely due to non-responding patients.

Precision medicine, as practiced today, typically considers a single target mutation to define disease subtypes and predict responsive patients. Yet to address the true complexity of disease biology, it likely takes more than one biomarker.


Auransa specifically targets this dilemma of patient heterogeneity

Auransa specifically targets this dilemma of patient heterogeneity, discovering and developing medicines for patient sub-populations not addressed by current approaches to deliver the optimal medicines to the right patients.

Through the predictive power of Auransa’s SMarTR™ Engine and CTSeek™ Liquid Biopsy technology, we are redefining precision medicine to develop novel therapeutics, identify specific patients more likely to respond in clinical trials and more accurately monitor patients’ responses to drugs.